Evidence map›Paper›PMID 25587036›Full record

ArticleBlood2015

Notch1 acts via Foxc2 to promote definitive hematopoiesis via effects on hemogenic endothelium.

Il Ho Jang, Yi-Fen Lu, Long Zhao, Pamela L Wenzel, Tsutomu Kume, Sumon M Datta, Natasha Arora, Jordi Guiu, Mounia Lagha, Peter G Kim and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 4 countries.

Il Ho JangStem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA; Stem Cell Transplantation Program, Manton Center for Orphan Disease Research, Children's Hospital Boston, Boston, MA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA; Harvard Stem Cell Institute, Boston, MA; Department of Physiology, School of Medicine, Pusan National University, Yangsan, Republic of Korea;
Yi-Fen LuStem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA; Stem Cell Transplantation Program, Manton Center for Orphan Disease Research, Children's Hospital Boston, Boston, MA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA; Harvard Stem Cell Institute, Boston, MA;
Long ZhaoCardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA;
Pamela L WenzelStem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA; Stem Cell Transplantation Program, Manton Center for Orphan Disease Research, Children's Hospital Boston, Boston, MA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA; Harvard Stem Cell Institute, Boston, MA;
Tsutomu KumeNorthwestern University, Chicago, IL;
Sumon M DattaStem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA;
Natasha AroraStem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA; Stem Cell Transplantation Program, Manton Center for Orphan Disease Research, Children's Hospital Boston, Boston, MA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA; Harvard Stem Cell Institute, Boston, MA;
Jordi GuiuCancer Research Program, Institut Hospital del Mar Investigacions Mediques, Barcelona, Spain; and.
Mounia LaghaCentre National de la Recherche Scientifique Unité de Recherche Associée 2578, Department of Developmental Biology, Pasteur Institute, Paris, France.
Peter G KimStem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA; Stem Cell Transplantation Program, Manton Center for Orphan Disease Research, Children's Hospital Boston, Boston, MA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA; Harvard Stem Cell Institute, Boston, MA;
Eun Kyoung DoDepartment of Physiology, School of Medicine, Pusan National University, Yangsan, Republic of Korea;
Jae Ho KimDepartment of Physiology, School of Medicine, Pusan National University, Yangsan, Republic of Korea;
Thorsten M SchlaegerStem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA; Harvard Stem Cell Institute, Boston, MA;
Leonard I ZonStem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA; Harvard Stem Cell Institute, Boston, MA;
Anna BigasCancer Research Program, Institut Hospital del Mar Investigacions Mediques, Barcelona, Spain; and.
Caroline E BurnsHarvard Stem Cell Institute, Boston, MA; Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA;
George Q DaleyStem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA; Stem Cell Transplantation Program, Manton Center for Orphan Disease Research, Children's Hospital Boston, Boston, MA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA; Harvard Stem Cell Institute, Boston, MA;
Harvard Stem Cell Institute · USDana-Farber/Boston Children's Cancer and Blood Disorders Center · USHarvard University · USHospital del Mar Research Institute · ESHoward Hughes Medical Institute · USPusan National University · KRDana-Farber Cancer Institute · USInstitut Pasteur · FRMassachusetts General Hospital · USNorthwestern University · US

Funding

Customized stem cells for clinical application in blood disordersR24DK092760 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI COLLINS, JAMES J, DALEY, GEORGE Q · 2011 to 2018
$10.7M
Human Pluripotent Stem Cell and Progenitor Models of Cardiac and Blood DiseasesU01HL100001 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI DALEY, GEORGE Q, ORKIN, STUART H · 2009 to 2015
$8.9M
Stem cells for therapeutics discovery in genetic blood disordersU01HL134812 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI DALEY, GEORGE Q, LIPTON, JEFFREY M · 2016 to 2022
$8.3M
EMBRYONIC HEMATOPOIESISR01HL048801 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 1992 to 2016
$5.7M
Identification of biomechanical pathways that promote hematopoiesisK01DK092365 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI WENZEL, PAMELA LYNN · 2011 to 2015
$708k
Howard Hughes Medical InstituteNHLBI NIH HHS R01 HL048801NHLBI NIH HHS U01 HL100001NHLBI NIH HHS U01 HL134812NHLBI NIH HHS UO1-HL100001NIDDK NIH HHS K01 DK092365NIDDK NIH HHS R24 DK092760NIDDK NIH HHS R24DK092760
6 · The paper itself

Abstract

Hematopoietic and vascular development share many common features, including cell surface markers and sites of origin. Recent lineage-tracing studies have established that definitive hematopoietic stem and progenitor cells arise from vascular endothelial-cadherin(+) hemogenic endothelial cells of the aorta-gonad-mesonephros region, but the genetic programs underlying the specification of hemogenic endothelial cells remain poorly defined. Here, we discovered that Notch induction enhances hematopoietic potential and promotes the specification of hemogenic endothelium in differentiating cultures of mouse embryonic stem cells, and we identified Foxc2 as a highly upregulated transcript in the hemogenic endothelial population. Studies in zebrafish and mouse embryos revealed that Foxc2 and its orthologs are required for the proper development of definitive hematopoiesis and function downstream of Notch signaling in the hemogenic endothelium. These data establish a pathway linking Notch signaling to Foxc2 in hemogenic endothelial cells to promote definitive hematopoiesis.

Indexed as

Gene Expression Regulation, DevelopmentalAnimalsApoptosisBlotting, WesternCell DifferentiationCell LineageCell ProliferationCells, CulturedEmbryonic Stem CellsEndothelium, VascularForkhead Transcription FactorsHematopoiesisHematopoietic Stem CellsMiceReal-Time Polymerase Chain ReactionReceptor, Notch1Forkhead Transcription Factorsmesenchyme fork head 1 proteinNotch1 protein, mouseReceptor, Notch1RNA, Messenger

Identifiers

PMID25587036
PMCPMC4342355
OpenAlexW2038790257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.